A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Trial Profile

A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Travoprost (Primary) ; Timolol
  • Indications Glaucoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 30 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top